1.
J Clin Nurs
; 2021 Aug 19.
Article
in English
| MEDLINE | ID: covidwho-2259328
2.
EJHaem
; 1(2): 545-547, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-837248
ABSTRACT
Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVID-19 pandemic. In emerging small case studies of SCD patients with COVID-19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion and Tocilizumab are evident. However, further clinical trials and larger cohort studies are essential to evaluate effective diagnostic and management options for this high-risk group.